title: Mesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs).
abstract: Heparin and heparan sulfate proteoglycans (HSPGs) stabilize FGFs which belong to heparin-binding growth factors (HBGFs) on active conformation. They also strongly potentiate their mitogenic activity on many cell types, and protect them against thermal denaturation and enzymatic degradation. In the present work we have tested two heparin-like substances named mesoglycan and sulodexide obtained from bovine intestinal mucosal extracts. These products are used as heparin, in various of therapeutic fields such as atherosclerosis or antithrombotic therapy. The compositions of mesoglycan and sulodexide are partially known and include chondroitin, dermatan and heparan sulfate. We have shown that mesoglycan and sulodexide potentiated the mitogenic activity of FGF1 and FGF2. The magnitude of this effect was identical with that of heparin used as a control substance but at double concentration. Mesoglycan and sulodexide also exerted stabilizing and protective effects on FGFs for heat denaturation and enzymatic degradation. The suppression of the protective properties after heparinase treatment of mesoglycan and sulodexide indirectly demonstrated the presence of heparan sulfate which was shown to represent about 60% of the commercial products.
authors.affiliation: Laboratoire de Recherche sur la Croissance Cellulaire, CNRS URA 1813, Université Paris, XII-Val de Marne, Creteil, France.
authors.forename: M
authors.initials: M
authors.lastname: Tardieu
authors.forename: M C
authors.initials: MC
authors.lastname: Bourin
authors.forename: P
authors.initials: P
authors.lastname: Desgranges
authors.forename: P
authors.initials: P
authors.lastname: Barbier
authors.forename: D
authors.initials: D
authors.lastname: Barritault
authors.forename: J P
authors.initials: JP
authors.lastname: Caruelle
mesh_terms: D000818:Animals; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D010450:Endopeptidases; D016220:Fibroblast Growth Factor 1 / Q000737:chemistry* / Q000494:pharmacology*; D016222:Fibroblast Growth Factor 2 / Q000737:chemistry* / Q000494:pharmacology*; D006025:Glycosaminoglycans / Q000302:isolation & purification / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000737:chemistry; D011489:Protein Denaturation; D011994:Recombinant Proteins / Q000737:chemistry / Q000494:pharmacology
chemical_list: D006025:Glycosaminoglycans; D000960:Hypolipidemic Agents; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; C007858:glucuronyl glucosamine glycan sulfate; C040617:mesoglycan; D006493:Heparin; D010450:Endopeptidases